BHVN
What one share of Biohaven holds
Pharmaceutical Preparations
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. We are advancing our innovative portfolio of therapeutics, leveraging our proven drug development experience and multiple proprietary drug development platforms.
Biohaven’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.48 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$3.90 |
| Cash and investments | $1.77 |
| Debt | $1.72 |
| Book value | $0.08 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$3.01 | $0.03 | −$1.96 | — | $0.43 |
| 2021 | — | −$5.43 | $0.02 | −$3.73 | — | — |
| 2022 | — | −$12.75 | $0.14 | −$6.79 | — | $7.90 |
| 2023 | — | −$5.73 | $0.04 | −$4.70 | — | $5.28 |
| 2024 | — | −$9.28 | $0.04 | −$6.43 | — | $4.18 |
| 2025 | — | −$6.86 | $0.01 | −$5.67 | — | $0.39 |